Recipharm completes Korean serialisation project for Abbott as the CDMO continues international roll out

Recipharm, the leading contract development and manufacturing organisation (CDMO), is pleased to announce further serialisation success with the completion of a complex serialisation project for Korea for one of its leading customers; Abbott. The initiative, which commenced in April 2014, is now completed. 

The CDMO met the precise customer and market requirement to produce a data matrix code, including serial number, with full compliance with complex regulations, similar to foreseen EU rules. 

Recipharm applied its internationally adaptable solution, designed to achieve full compliance with country specific regulations, to a blister packaging line; with the need differing markedly from Chinese serialisation. Validation batches are now manufactured released and planned to be shipped to Korea mid-March 2015.

Recipharm applied its successful methodology to the project initiated for the top ten pharmaceutical customer. From the outset, integration formed a key tenet with the establishment of joint company strategic teams and the sharing of critical information. Costs were kept to a minimum and full implementation achieved.   

Stephane Guisado, General Manager at Recipharm in Fontaine commented: “We are delighted with the success of this serialisation project for the Korean market carried out for Abbott, a long standing pharma partner of ours. Once again, our serialisation platform solution has proved the extent of its adaptability and resourcefulness for differing geographic and multi-country regulatory requirements. Indeed, in this case, it ensured that our customer complied in full with the relevant serialisation regulations set down by Korea”,

He continued: “We were pleased to have received such strong thanks and recognition from the Abbott project team for the work that we staged on this project. We look forward to rolling out further projects during 2015.” 

Read more about serialisation here

Contact information
Stephane Guisado, General Manager Recipharm Fontaine, stephane.guisado@recipharm.com,
+ 33 3 8044 78 33
Amine Tahiri, Commercial Manager Recipharm Fontaine, amine.tahiri@recipharm.com,
+ 33 8044 78 05

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail: t.jervis@defacto.com or a.heeley@defacto.com
Tel: +44 (0) 207 861 3019/3043

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees.  Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.  

For more information on Recipharm and our services, please visit www.recipharm.com        

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden,  Telephone 46 8 602 52 00,  Fax  46 8 81 87 03

www.recipharm.com

Tags:

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com

Subscribe

Documents & Links

Quotes

We are delighted with the success of this serialisation project for the Korean market carried out for Abbott, a long standing pharma partner of ours.
Stephane Guisado